Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA
Teva said the drug could improve treatment adherence, and Medincell may receive up to $112 million in milestone payments plus royalties.
- Teva said it received U.S. Food and Drug Administration approval for Weltruza, a once-monthly injection for adults with schizophrenia.
- Teva expects to launch Weltruza in the United States in the coming weeks.
- Weltruza is the second U.S.-approved product from Teva’s partnership with French biotech company Medincell, following Uzedy.
- Medincell may receive up to $112 million in additional milestone payments, plus sales royalties, under its agreement with Teva.
11 Articles
11 Articles
Teva wins FDA approval for monthly schizophrenia injection Weltruza - Regional Media News
(Corrects sourcing in bullet 3, updates share reaction in bullet point 5) Oct 9 (Reuters) - Teva said on Friday it had received approval from the US Food and Drug Administration for Weltruza, a once-monthly injection for adults with schizophrenia. Weltruza is the second US-approved [...]
Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA
Teva Pharmaceutical Industries (NYSE:TEVA) said the U.S. Food and Drug Administration has approved WELTRUZA, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for schizophrenia. Chief Executive Officer Richard Francis said the approval represents another step in Teva’s “P
The Israeli pharmaceutical company's stock jumped over 4% in early trading after it reported that it had received FDA approval for the drug WELTRUZA, for the treatment of schizophrenia.
Coverage Details
Bias Distribution
- 43% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
